Machine Learning in Bioprocess Development: Where We Are and Where We Could Go

Machine Learning is believed to be a game changer for the industry, especially by big Pharma as reflected by significant investments. Starting from an introduction to machine learning, this contribution outlines the current machine learning status for process development with examples, provides future directions towards more global high-value machine learning centric development, concepts to engage people in the digital evolution and ideas for machine learning centric business models.
Presented by Rui Portela, Senior Data Scientist, GlaxoSmithKline Vaccines

Rui Portela works as Senior Data Scientist at Global Data Analytics and Innovation group in Technical R&D of GSK Biologicals, Belgium. He is a molecular and cell biologist, with a MSc in biotechnology from the New University of Lisbon (UNL) and PhD in Bioengineering Systems (MIT-Portugal program – UNL). Previously, Rui worked on model based bioprocess optimization at GSK and IBET as research scientist, applying metabolic network analysis, PAT, simulation of molecular processes and hybrid modeling methods to enable more efficient process operation/design.
Followed by Klaus Mauch, CEO at Insilico Biotechnology AG

Klaus Mauch is one of Insilico’s co-founders and became managing director in 2004 and CEO in 2006. In his previous role as CTO, he was responsible for the design and development of Insilico’s modelling and simulation platform where he established novel methods for the computer-aided construction of cellular networks. Before that, he gained extensive experience in metabolic engineering and applied systems biology as a group leader at the Institute of Biochemical Engineering, University of Stuttgart. He was awarded a Master’s degree in Chemical Engineering by the Technical University of Karlsruhe, Germany. Klaus is a member of the Advisory Board of the Division Systems Biology and Synthetic Biology of DECHEMA, board member of the Industrial Association White Biotechnology (IWBio), and board member of the Association of German Biotechnology Companies (VBU).
Sponsored by Insilico Biotechnology AG

Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Groundbreaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.